UK interest rate cuts looking less imminent is not ideal news for real estate but at the same time, it is not a disaster either, according to analysts at Shore Capital.
“The best businesses have evolved to become far more than just binary plays on interest rates and leverage, developing genuine value-added strategies to drive continued growth through the property cycle,” it says.
Barclays maintains a broadly optimistic view on the earnings outlook for UK banks, foreseeing a recovery in net interest margins (NIM) over the coming quarters, with a favourable view on NatWest in particular.
Barclays expects its lending competitor to surpass first-quarter earnings guidance on 26 April and to post an upward revision to its full-year guidance.
Brokerage Shore Capital Markets expressed optimism on Quadrise PLC (AIM:QED)’s progress in Utah following a Friday update.
Quadrise revealed that drilling at Asphalt Ridge is scheduled to start next week, with completion anticipated before the end of April.
Stifel, in its latest investment research note, underscores hVIVO PLC's robust standing in the global healthcare market, particularly in conducting human challenge clinical trials (HCTs) for infectious and respiratory diseases.
The investment bank forecasts hVIVO's revenue to reach £62 million in 2024, an estimation deemed highly achievable given the company's current contracted order book of £80 million as of the end of 2023. This order book represents a firm foundation, with 90% of the 2024 revenue already contracted and clear visibility extending into 2025.
adidas AG is likely to continue enjoying improved profit and sales over the coming years after unveiling stronger first-quarter trading earlier this week, analysts have said.
adidas bumped up full-year guidance midweek after beating first-quarter expectations on stronger profit margins and sales of footwear products.
Stifel is projecting peak worldwide sales of $364 million by 2029 for Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s Eroxon, an innovative gel-based treatment for erectile dysfunction (ED).
According to the US investment bank, most of these sales, $223 million, are expected from the US market, with Europe contributing an additional $117 million by 2028.